• search

Ranbaxy acquires Ethimed in Belgium

Written by: Staff
|

New Delhi, Mar 30 (UNI) Continuing its expansion in the fast growing European drug market, India's largest pharmaceutical company Ranbaxy Laboratories today said it had acquired a generics Company Ethimed NV, in Belgium.

Ranbaxy said the Belgian market is the seventh largest pharmaceutical market in Europe. It did not indicate the value of the acquisition.

This is the third global acquisition in three days by Ranbaxy.

Prior to this, Ranbaxy yesterday bought 96.7 per cent stake in Romania's fifth largest pharma company Terapia from Boston-based private equity investors Advent International Corp for 324 million dollars.

The company has also bought Allen SpA-GlaxoSmithKline Plc's generic business in Italy-on Tuesday for an undisclosed amount.

The move will allow the Company to anticipate local market dynamics and capitalise on the changing business landscape in the Benelux countries.

A large number of Indian companies are making a beeline for the European market, where drugs worth billions of dollars are expected to go off patent in the next few years.

The Belgian market is largely a branded, high priced market with increasing generic penetration.

The acquisition positions the Company favourably to capture a significant position of this expanding market.

UNI SR SS DS1610

For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X

Loksabha Results

PartyLWT
BJP+8346354
CONG+38790
OTH79198

Arunachal Pradesh

PartyLWT
BJP43135
JDU077
OTH2911

Sikkim

PartyWT
SKM01717
SDF01515
OTH000

Odisha

PartyLWT
BJD3874112
BJP91524
OTH3710

Andhra Pradesh

PartyLWT
YSRCP0150150
TDP02424
OTH011

-
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more